Our non-antibiotic macrolide platform addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases.

Tackling one of the world's most prevalent diseases

Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.

The unmet need for disease-modifying therapies for COPD

There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.

A new paradigm of epithelial barrier insufficiency

Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.

CONTACT US

CONTACT DETAILS

Eiðistorg 13

170 Seltjarnarnes

Iceland

[+354] 454 0090

SEND US A MESSAGE